• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Press Release: EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries

Press Release: EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries

by Elena Iemma | Apr 7, 2020 | News

PROVIDENCE, RI, April 7, 2020 /PRNewswire/ — EpiVax, Inc., is using advanced computational tools to accelerate a COVID-19 vaccine candidate (EPV-CoV19) for healthcare workers (HCW) into clinical trials in 6 months. Today, EpiVax announces its partnership with...
Providence biotech firm is working on a coronavirus vaccine – Boston Globe interview

Providence biotech firm is working on a coronavirus vaccine – Boston Globe interview

by Elena Iemma | Mar 30, 2020 | News

With 22 years of experience, EpiVax is in the ‘perfect position’ to figure out how to immunize people, founder says By Edward Fitzpatrick Globe Staff,Updated March 30, 2020, 6:00 a.m. Read the full text here. The Boston Globe’s weekly Ocean State Innovators column...
Press Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

Press Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

by Elena Iemma | Mar 24, 2020 | News

March 24, 2020 Niel, Belgium: eTheRNA Immunotherapies nv (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and...
Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding – WPRI News Channel 12 interview

Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding – WPRI News Channel 12 interview

by Elena Iemma | Mar 20, 2020 | News

Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding by: Sarah Doiron, Logan Wilber Posted: Mar 19, 2020 / 06:00 PM EDT / Updated: Mar 19, 2020 / 06:33 PM EDT Find the full story here. PROVIDENCE, R.I. (WPRI) ─ As the country races to stem the...
Providence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview

Providence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview

by Elena Iemma | Mar 20, 2020 | News

Providence biotech company working to create coronavirus vaccine by TAMARA SACHARCZYK, NBC 10 NEWS Wednesday, March 18th 2020 Find the full story here EpiVax in Providence. (WJAR) A team of local scientists are on the front lines of a global pandemic as they race...
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
  • EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 
  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}